REG - Ovoca Bio PLC - Directorate Change

Ovoca BioAnnouncement

30/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211230:nRSd9897Wa&default-theme=true

RNS Number : 9897W  Ovoca Bio PLC  30 December 2021

Ovoca Bio plc

("Ovoca" or the "Company")

 

Directorate Change

Ovoca Bio plc (LSE: OVB; ISE: OVXA) announces that Dr. Romulo Colindres has
informed the Board of his decision to step down as a Non-Executive Director of
the Company, with immediate effect, for both personal and business reasons.
Dr. Colindres stated: "It has been a pleasure to be involved with the Ovoca
board and team and wish them much success along the path to making orenetide
available to patients".

Kirill Golovanov, CEO of Ovoca, commented: "On behalf of the Company, I would
like to thank Romulo for his contribution to the board of Ovoca. We wish
Romulo well in his future endeavours."

 

End

 

For further information:

Ovoca Bio plc

Kirill Golovanov (Chief Executive)

Tel +353 1 661 9819

info@ovocabio.com (mailto:info@ovocabio.com)

 

Davy (Nominated Adviser, Euronext Growth Advisor and Broker)

John Frain / Daragh O'Reilly

Tel: +353 1 679 6363

 

Consilium Strategic Communications

Chris Gardner, Chris Welsh, Carina Jurs

ovocabio@consilium-comms.com

Tel: +44 (0)20 3709 5700

 

 

About Ovoca Bio

Ovoca Bio is a European-based biopharmaceutical company with a focus on
women's health. The Company is currently developing a novel treatment for
women with hypoactive sexual desire disorder (HSDD).

 

The Company's lead product, BP-101, a novel synthetic peptide administered
through a nasal spray, is clinically validated, with Phase II and Phase III
studies conducted in Russia demonstrating statistically significant
improvement in a number of key efficacy outcomes, including an increase in
female sexual desire and reduction of symptoms of distress associated with
HSDD.

 

Ovoca Bio is seeking to develop the drug for major global markets - in
particular the United States and Europe, as well as obtain marketing
approval in the Russian Federation.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUKVRRASUUUUA